Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-14-049649
Filing Date
2014-08-14
Accepted
2014-08-14 09:02:44
Documents
11
Period of Report
2014-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q v385761_10q.htm 10-Q 222429
2 EXHIBIT 31.1 v385761_ex31-1.htm EX-31.1 7413
3 EXHIBIT 31.2 v385761_ex31-2.htm EX-31.2 7352
4 EXHIBIT 32.1 v385761_ex32-1.htm EX-32.1 4716
5 EXHIBIT 32.2 v385761_ex32-2.htm EX-32.2 4625
  Complete submission text file 0001144204-14-049649.txt   1740774

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT casi-20140630.xml EX-101.INS 166389
7 XBRL TAXONOMY EXTENSION SCHEMA casi-20140630.xsd EX-101.SCH 20047
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE casi-20140630_cal.xml EX-101.CAL 16812
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE casi-20140630_def.xml EX-101.DEF 111050
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20140630_lab.xml EX-101.LAB 160649
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20140630_pre.xml EX-101.PRE 127573
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

EIN.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-20713 | Film No.: 141039691
SIC: 2836 Biological Products, (No Diagnostic Substances)